Personal information

Activities

Employment (3)

Fondazione IRCCS Istituto Nazionale dei Tumori: Milano, Lombardia, IT

2015-09 to present | post-doc (Research Department)
Employment
Source: Self-asserted source
Alessandra Cataldo

Ohio State University: Columbus, OH, US

2014 to 2015 | Post-doc
Employment
Source: Self-asserted source
Alessandra Cataldo

Fondazione IRCCS Istituto Nazionale dei Tumori: Milano, Lombardia, IT

2011 to 2014 | PhD student (Experimental Oncology)
Employment
Source: Self-asserted source
Alessandra Cataldo

Education and qualifications (3)

Università degli Studi di Milano: Milano, Lombardia, IT

2011 to 2014 | Dottorato in Patologia e Neuropatologie sperimentali
Education
Source: Self-asserted source
Alessandra Cataldo

Università degli Studi di Milano: Milano, Lombardia, IT

2008 to 2010 | Laurea magistrale in Biotecnologie mediche e medicina molecolare
Education
Source: Self-asserted source
Alessandra Cataldo

Seconda Università degli Studi di Napoli: Napoli, Campania, IT

2005 to 2008 | Laurea triennale in Biotecnologie
Education
Source: Self-asserted source
Alessandra Cataldo

Professional activities (2)

Solidarietà in Oncologia San Pietro e San Marco Onlus : Bergamo, IT

2017 | Prize “Marzia Galli Kienle”
Distinction
Source: Self-asserted source
Alessandra Cataldo

Società Italiana di Cardiologia: Rome, IT

2017 | AACR Scholar-in-Training Award
Distinction
Source: Self-asserted source
Alessandra Cataldo

Funding (7)

Study of microRNAs to overcome Trastuzumab resistance in HER2 positive breast cancer patients.

2020-01 to 2020-12 | Salary award
Fondazione Umberto Veronesi (Milan, Lombardia, IT)
Source: Self-asserted source
Alessandra Cataldo

Overcoming Trastuzumab resistance with microRNAs

2020 to 2021 | Grant
Ministero della Salute (Rome, IT)
Part of GRANT_NUMBER:

GR-2016-02361750

Source: Self-asserted source
Alessandra Cataldo

Mir-9 mediates resistance to chemotherapy by boosting an immunosuppressive tumor microenvironment in triple negative breast cancer

2019-03 to 2020-02 | Salary award
Fondazione Umberto Veronesi (Milan, IT)
Source: Self-asserted source
Alessandra Cataldo

MiR-302b-mediated BRCAness improves sensitivity to PARP inhibitors in BRCA not-mutated TNBC

2018-03 to 2019-02 | Salary award
Fondazione Umberto Veronesi (Milan, IT)
Source: Self-asserted source
Alessandra Cataldo

miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple negative breast cancer

2017-03 to 2018-02 | Salary award
Fondazione Umberto Veronesi (Milan, IT)
Source: Self-asserted source
Alessandra Cataldo

miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple negative breast cancer

2017 to present | Award
American Association for Cancer Research (PA, PA, US)
Source: Self-asserted source
Alessandra Cataldo

Exosome-mediated transfer of miR-302b to tumor cells as a mechanism exploited by CpG-activated immune system to improve response to cisplatin

2014 to 2015 | Salary award
Fondazione Libi e Andrea Lorini (Milano, IT)
Source: Self-asserted source
Alessandra Cataldo

Works (1)

MicroRNAs and DNA-damaging drugs in breast cancer: Strength in numbers

Frontiers in Oncology
2018 | Journal article
EID:

2-s2.0-85053115544

Part of ISSN: 2234943X
Contributors: Plantamura, I.; Cosentino, G.; Cataldo, A.
Source: Self-asserted source
Alessandra Cataldo via Scopus - Elsevier

Peer review (1 review for 1 publication/grant)

Review activity for Clinical and translational medicine. (1)